Related Experiment Video
Updated: Sep 30, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Using the NYHA Classification as Forecasting Tool for Hospital Readmission and Mortality in Heart Failure Patients
Ioana Mihaela Citu1, Cosmin Citu2, Florin Gorun2
1Department of Internal Medicine I, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Insights
Patients with advanced heart failure (HF) face higher mortality and rehospitalization risks when hospitalized with COVID-19. The New York Heart Association (NYHA) classification effectively predicts severe outcomes in these cardiac patients.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- Heart failure (HF) is a significant comorbidity, particularly in Romania, increasing COVID-19 severity and hospitalization risks.
- Patients with underlying cardiac conditions, especially heart failure, are disproportionately affected by SARS-CoV-2 infection.
Purpose of the Study:
- To evaluate the New York Heart Association (NYHA) classification as a prognostic tool for COVID-19 patients with heart failure.
- To assess the correlation between NYHA classification and in-hospital mortality, hospitalization duration, and rehospitalization probability for HF decompensation.
Main Methods:
- A retrospective study analyzing hospitalized COVID-19 patients with heart failure in Romania.
- Utilized the NYHA classification to stratify patients based on heart failure severity.
- Examined in-hospital mortality, length of stay, ICU admission, complications, and rehospitalization rates.
Main Results:
- Advanced NYHA classes (III and IV) were associated with significantly higher rates of comorbidities, mortality, and longer hospitalizations.
- NYHA IV patients experienced a median hospitalization of 20 days with a 47.8% in-hospital mortality rate.
- Severe complications and ICU admission were key predictors of mortality and rehospitalization, respectively. All NYHA IV survivors required rehospitalization within a month.
Conclusions:
- The NYHA classification is a valuable prognostic tool for stratifying risk in COVID-19 patients with heart failure.
- Physicians and policymakers must consider the high vulnerability and readmission risk of HF patients post-COVID-19 for discharge and monitoring strategies.
- HF patients remain at elevated risk for adverse outcomes following SARS-CoV-2 infection, necessitating tailored post-discharge care.
Abstract:
During the COVID-19 pandemic, it was observed that patients with heart disease are more likely to be hospitalized and develop severe COVID-19. Cardiac disease takes the top position among patient comorbidities, heart failure (HF) prevalence reaching almost 5% in the general population older than 35 years in Romania. This retrospective study aimed to determine the potential use of the NYHA classification for HF in hospitalized patients with COVID-19 as prognostic tool for in-hospital mortality, length of hospitalization, and probability of rehospitalization for HF decompensation. We observed that patients with advanced HF had a history of significantly more comorbid conditions that are associated with worse disease outcomes than the rest of patients classified as NYHA I and II. However, regardless of existing diseases, NYHA III, and, especially, NYHA IV, patients were at greatest risk for mortality following SARS-CoV-2 infection. They required significantly longer durations of hospitalization, ICU admission for mechanical ventilation, and developed multiple severe complications. NYHA IV patients required a median duration of 20 days of hospitalization, and their in-hospital mortality was as high as 47.8%. Cardiac biomarkers were significantly altered in patients with SARS-CoV-2 and advanced HF. Although the study sample was small, all patients with NYHA IV who recovered from COVID-19 required a rehospitalization in the following month, and 65.2% of the patients at initial presentation died during the next six months. The most significant risk factor for mortality was the development of severe in-hospital complications (OR = 4.38), while ICU admission was the strongest predictor for rehospitalization (OR = 5.19). Our result highlights that HF patients continue to be vulnerable post SARS-CoV-2 infection. Physicians and policymakers should consider this population's high likelihood of hospital readmissions when making discharge, hospital capacity planning, and post-discharge patient monitoring choices.
More Related Videos
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VII: Nursing Interventions
Heart Failure V: Medical Management
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations

